Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Allergic Asthma
Interventions: omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more

Conditions: Asthma
Interventions: AZD8630, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more

Conditions: Asthma, Allergic
Interventions: REGN3500, Dupilumab, Placebo, Fluticasone propionate; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Asthma
Interventions: Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more

Conditions: Asthma
Interventions: QAW039, Montelukast, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more

Conditions: Mild to Moderate Asthma
Interventions: fluticasone propionate, formoterol fumarate, fluticasone propionate, formoterol fumarate; Drug · Other
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Anaheim, California • Mission Viejo, California • Denver, Colorado + 5 more

Conditions: Asthma
Interventions: Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Riverside, California + 18 more

Conditions: Asthma
Interventions: FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more

Conditions: Asthma
Interventions: Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 22
States / cities: Encinitas, California • Lancaster, California • Los Angeles, California + 19 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Sirukumab, Placebo, Rescue medication; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 5
States / cities: Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more

Conditions: Asthma
Interventions: Montelukast 10 mg orally, Placebo; Drug · Other
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Asthma, GERD
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more

Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions: Dexpramipexole Dihydrochloride, Placebo; Drug
Lead sponsor: Areteia Therapeutics; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 76
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more

Conditions: Asthma
Interventions: dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more

Conditions: Asthma
Interventions: Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more

Conditions: Asthma
Interventions: Xolair; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Asthma
Interventions: PLACEBO, MEDI528 9 mg/kg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more

Conditions: Asthma, Status Asthmaticus
Interventions: Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more

Search by objective public record fields.

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

Study of REGN3500 and Dupilumab in Patients With Asthma

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

Dose Finding Study for QAW039 in Asthma

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

Asthma in the Elderly: The Effect of Montelukast

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

Moderate to Persistent Asthma in the Obese Subject

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma